Role of Imiquimod in Skin Cancer Treatment
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 5 (6) , 453-458
- https://doi.org/10.2165/00128071-200405060-00010
Abstract
Cancer of the skin is by far the most common form of all cancers. Given the increasing incidence of skin cancer worldwide, it seems feasible to reconsider the treatment options available for dealing...Keywords
This publication has 38 references indexed in Scilit:
- Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier ImiquimodJNCI Journal of the National Cancer Institute, 2003
- Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potentialClinical and Experimental Dermatology, 2002
- Nonmelanoma skin cancerCurrent Treatment Options in Oncology, 2002
- Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathwayNature Immunology, 2002
- Immunotherapy for nonmelanoma skin cancerCancer, 2002
- Topical immunomodulators—progress towards treating inflammation, infection, and cancerThe Lancet Infectious Diseases, 2001
- Risk of Developing a Subsequent Nonmelanoma Skin Cancer in Patients With a History of Nonmelanoma Skin CancerArchives of Dermatology, 2000
- Imiquimod, a Topical Immune Response Modifier, Induces Migration of Langerhans Cells11The authors have declared a conflict of interest.Journal of Investigative Dermatology, 2000
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999
- Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and ImiquimodCellular Immunology, 1999